Latest Administration News

Adslot Technologies has formalised a Deed of Company Arrangement following voluntary administration, aiming to satisfy non-related creditors while maintaining group control of its digital advertising platform.

AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.

News Corp posted a 7% revenue increase to $9.028 billion in fiscal 2026, driven by gains across its key segments, while net income attributable to stockholders fell 51% due to absence of prior discontinued operations income.

Connected Minerals (ASX:CML) is mobilising a ~6,000m reverse circulation and diamond drilling program at its Bailundo Carbonatite Project in Angola, aiming to define a maiden JORC Mineral Resource for niobium and rare earth elements.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Dome Gold Mines (ASX:DME) is raising up to AUD 2 million through unsecured convertible notes to accelerate its Sigatoka feasibility study, mining lease application, and copper-gold exploration amid rising metal prices.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

Clarity Pharmaceuticals reveals encouraging early results from the SECuRE trial, with substantial PSA reductions and multiple complete responses at the 8 GBq 67Cu-SAR-bisPSMA dose level in advanced prostate cancer patients.

AdAlta’s lead CAR-T therapy EW-001 has achieved a rare clinical milestone with one mesothelioma patient remaining cancer-free two years after treatment, and a second reaching one-year survival, underscoring the therapy’s potential durability in a notoriously difficult cancer.

JPMorgan Asset Management has revised the estimated cash distributions for its four Equity Premium Income Complex ETFs for August 2026, with payments scheduled mid-month.

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.

Mandrake Resources has strategically refined its Utah Lithium Project tenure by securing three key SITLA leases in the project’s central zone and relinquishing marginal blocks, positioning itself for upcoming bulk lithium brine production and technical evaluation.